T. Rowe Price Associates’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
|
|||||
|
2024
Q2 | $2.18M | Sell |
|
|||||
|
2024
Q1 | $14.2M | Sell |
|
|||||
|
2023
Q4 | $30.6M | Sell |
|
|||||
|
2023
Q3 | $120M | Buy |
|
|||||
|
2023
Q2 | $166M | Buy |
|
|||||
|
2023
Q1 | $117M | Sell |
|
|||||
|
2022
Q4 | $152M | Buy |
|
|||||
|
2022
Q3 | $135M | Sell |
|
|||||
|
2022
Q2 | $166M | Sell |
|
|||||
|
2022
Q1 | $227M | Buy |
|
|||||
|
2021
Q4 | $195M | Buy |
|
|||||
|
2021
Q3 | $172M | Buy |
|
|||||
|
2021
Q2 | $85.2M | Sell |
|
|||||
|
2021
Q1 | $46.7M | Buy |
|
|||||
|
2020
Q4 | $54M | Buy |
|